YUKON

FIRAZYR is covered by Yukon Pharmacare and Extended Health Benefits programs (Exception Drug Status Program)

Eligibility

For FIRAZYR to be eligible for coverage by Yukon Pharmacare, prescribers must submit an Exception Drug Status Application. Deductibles may apply. For more information concerning the reimbursement process, contact OnePath®.

Reimbursement Criteria

We are pleased to inform you that FIRAZYR (icatibant acetate) is reimbursed in Yukon for your hereditary angioedema (HAE) patients who meet the following criteria:

For the treatment of acute attacks of HAE in adults with lab confirmed C1-esterase inhibitor deficiency (type I or II) if the following conditions are met:

Treatment of non-laryngeal attacks of at least moderate severity, OR
Treatment of acute laryngeal attacks, AND
Limited to a single dose for self-administration per attack, AND
Prescribed by a physician with experience in the treatment of HAE

OnePath® Patient Support Program will help navigate insurance coverage and access reimbursement to medication through private and public insurance companies.

Find Out More

Source: Yukon Drug Formulary. April 2022.
https://ihs.gov.yk.ca/drugs